Jan 24, 2023
Naveen Pemmaraju, MD, is the Director of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program and an Associate Professor of Cancer Medicine at MD Anderson Cancer Center. He also serves as the Executive Director of Cancer Medicine for the MDACC Cancer Network. He is a principal investigator for several national clinical trials in MPNs, AML, and BPDCN, and he has helped develop novel targeted therapies for patients with these disorders. He led a multicenter team in a phase 1/2 clinical trial for patients with BPDCN that ultimately led to U.S. Food and Drug Administration (FDA) approval for the first targeted agent available for this rare leukemia. He has authored/co-authored over 315+ publications and has been awarded the Gerald P. Bodey Award for Excellence in Education from MD Anderson.